The past, present, and future treatment of BRAFV600‐mutant metastatic colorectal cancer: A comprehensive review
BRAFV600‐mutant metastatic colorectal cancer comprises a biologically distinct and clinically aggressive subset of metastatic colorectal cancer. Early attempts to apply single‐agent BRAFV600 inhibition failed because of rapid acquired resistance and reactivation of mitogen‐activated protein kinase signaling. Over the l...